# A Study of Oral Gimatecan in Platinum-Resistant Epithelial Ovarian, Fallopian Tube or Peritoneal Cancer

> **NCT04846842** · PHASE2 · UNKNOWN · sponsor: **Lee's Pharmaceutical Limited** · enrollment: 46 (estimated)

## Conditions studied

- Epithelial Ovarian Cancer
- Fallopian Tube Cancer
- Peritoneal Cancer

## Interventions

- **DRUG:** Gimatecan

## Key facts

- **NCT ID:** NCT04846842
- **Lead sponsor:** Lee's Pharmaceutical Limited
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2021-07-01
- **Primary completion:** 2022-07-01
- **Final completion:** 2023-07-01
- **Target enrollment:** 46 (ESTIMATED)
- **Last updated:** 2021-04-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04846842

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04846842, "A Study of Oral Gimatecan in Platinum-Resistant Epithelial Ovarian, Fallopian Tube or Peritoneal Cancer". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT04846842. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*